We present a review of our hybrid management (endovascular + open surgery) of large thoracic aortic aneurysms (>80mm). The strategy comprises a primary endovascular repair using Thoracic Endovascular Aortic Repair (TEVAR), and/or Fenestrated and Branched endografts (FBEVAR), followed by open thoracotomy and aneurysmorraphy, specifically without the need for aortic cross-clamping. We performed a retrospective review of all patients who had undergone aneurysmorraphy via thoracotomy following TEVAR & FBEVAR in two high volume aortic centers between December 2017 and March 2024. We performed aneurysmorraphy in two clinical situations: 1) in the setting of a planned staged treatment, shortly after TEVAR or FBEVAR in young patients with aneurysm diameter > 100mm; and 2) as a secondary intervention during follow-up for patients with persistent sac enlargement and aneurysm diameters > 80mm. The primary end-points were 30-day survival and aneurysm related mortality during follow-up. Secondary endpoints were sac size evolution, peri-operative and post-operative complications, freedom from further re-intervention and late aortic complications. Twelve patients underwent aneurysmorraphy following TEVAR and/or FBEVAR during the study period. Mean patient age was 60 +/- 12 years, and the mean sac diameter before thoracotomy was 101 +/- 25 mm. Endovascular embolization of intercostal arteries prior to aneurysmorraphy was performed in 4 patients. The 30-day survival rate was 100%. During the mean follow up period of 21 months, 2 patients died - one of COVID and another of intra-cerebral hemorrhage. No aneurysm-related mortality occurred and sac regression was achieved in all patients except one experiencing aortic growth below the aneurysmorraphy. This study demonstrates that thoracic aneurysmorraphy performed after TEVAR and FBEVAR for complex thoracic aneurysms is a safe and effective technique. This procedure allows the eradication of endoleaks and an immediate sac volume reduction, which prevents aorta-bronchial or esophageal fistulation and secures the endovascular repair; the reduction of the aneurysm mass effect restores normal lung parenchyma expansion. This hybrid management strategy drastically reduces the morbidity associated with standard open surgery performed for thoracic endograft explantation.